首页 › 基金 › Avoro Capital Advisors LLC › SYRE
Avoro Capital Advisors LLC 对 SYRE 的持仓历史
SPYRE THERAPEUTICS INC · 医疗保健
Avoro Capital Advisors LLC 在 Q3 2026 的 13F 申报中披露持有 SYRE(SPYRE THERAPEUTICS INC)2,598,973 股,市值约 US$47.8M,约占其申报组合的 0.49%,在其申报持仓中市值排名第 23 位。 Avoro Capital Advisors LLC 最近 13 个申报季度中有 6 个季度披露了 SYRE 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Avoro Capital Advisors LLC 对 SYRE 的持仓演变
Avoro Capital Advisors LLC 于 Q3 2023 首次披露 SYRE 持仓:11,458 股(约 US$140K)。 该持仓在 Q1 2024 达到峰值 1,839,138 股,市值约 US$69.8M。 在 6 次申报中,Avoro Capital Advisors LLC 1 次增持、1 次减持、2 次保持不变。 最近一期申报(Q3 2026)显示持股 2,598,973 股、市值约 US$47.8M。 持仓曾出现大幅变动:Q4 2023 增持约 15951% (随后一个季度股价上涨 9%)、Q3 2024 减持约 67%。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 11.46K | $140.36K | 新进 |
| Q4 2023 | 1.84M | $39.58M | 增持 |
| Q1 2024 | 1.84M | $69.76M | 持有 |
| Q2 2024 | 1.84M | $43.24M | 持有 |
| Q3 2024 | 598.60K | $17.60M | 减持 |
| Q3 2026 | 2.60M | $47.83M | 新进 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 SYRE 与 13F 数据
SYRE(SPYRE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 64 只申报持有 SYRE,申报仓位最大的包括:Paradigm Biocapital Advisors LP (US$396.8M), PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$328.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 SYRE 的基金
- Paradigm Biocapital Advisors LP 4.46M 股 · $396.85M · Q3 2026
- PERCEPTIVE ADVISORS LLC 4.32M 股 · $383.48M · Q2 2026
- RTW INVESTMENTS, LP 3.69M 股 · $328.68M · Q3 2026
- Venrock Adviser, LLC 2.99M 股 · $265.05M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 2.76M 股 · $245.76M · Q3 2026
- TCG Crossover Management, LLC 1.90M 股 · $169.21M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 1.89M 股 · $167.99M · Q2 2026
- Affinity Asset Advisors, LLC 1.28M 股 · $113.88M · Q3 2026
- Remedium Capital Partners, LLC 1.16M 股 · $103.33M · Q3 2026
- BRAIDWELL LP 879.47K 股 · $78.08M · Q2 2026
- Siren, L.L.C. 868.60K 股 · $77.33M · Q3 2026
- Commodore Capital LP 846.79K 股 · $75.18M · Q2 2026
更多关于 Avoro Capital Advisors LLC
常见问题
How long has Avoro Capital Advisors LLC held SYRE?
Avoro Capital Advisors LLC has disclosed SYRE holdings in 6 of the last 13 reported quarters, going back to Q3 2023.
What is Avoro Capital Advisors LLC's current position in SYRE?
As of Q3 2026, Avoro Capital Advisors LLC holds 2.60M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $47.83M, representing 0.49% of its reported portfolio and ranking #23.
Has Avoro Capital Advisors LLC been buying or selling SYRE?
In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC newly opened its position in SYRE. The position peaked in Q1 2024 at 1.84M shares.
Which other funds hold SYRE?
Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.